



**Universiteit
Leiden**
The Netherlands

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Zewinger, S.; Kleber, M.E.; Tragante, V.; McCubrey, R.O.; Schmidt, A.F.; Direk, K.; ... ;
GENIUS-CHD Consortium

Citation

Zewinger, S., Kleber, M. E., Tragante, V., McCubrey, R. O., Schmidt, A. F., Direk, K., ... Speer, T. (2017). Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. *The Lancet Diabetes And Endocrinology*, 5(7), 534-543.
doi:10.1016/S2213-8587(17)30096-7

Version: Not Applicable (or Unknown)
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/114866>

Note: To cite this publication please use the final published version (if applicable).



Published in final edited form as:

Lancet Diabetes Endocrinol. 2017 July ; 5(7): 534–543. doi:10.1016/S2213-8587(17)30096-7.

Relations between lipoprotein(a) concentrations, *LPA* genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

A full list of authors and affiliations appears at the end of the article.

Summary

Background—Lipoprotein(a) concentrations in plasma are associated with cardiovascular risk in the general population. Whether lipoprotein(a) concentrations or *LPA* genetic variants predict long-term mortality in patients with established coronary heart disease remains less clear.

Methods—We obtained data from 3313 patients with established coronary heart disease in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. We tested associations of tertiles of lipoprotein(a) concentration in plasma and two *LPA* single-nucleotide polymorphisms ([SNPs] rs10455872 and rs3798220) with all-cause mortality and cardiovascular mortality by Cox regression analysis and with severity of disease by generalised linear modelling, with and without adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy. Results for plasma lipoprotein(a) concentrations were validated in five independent studies involving 10 195 patients with established coronary heart disease. Results for genetic

Correspondence to: Prof Winfried März, Medical Clinic V, Medical Faculty of Mannheim, University Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany winfried.maerz@medma.uni-heidelberg.de.

*Contributed equally

See **Online** for appendix

For the **GENIUS-CHD consortium** see <http://www.genius-chd.com>

Contributors

SZ, UL, DR, SB, RBS MSN, AMR, RND, RC-D, JJ, FB, LW, IK, AH, HS, WM, and TSp designed the study. SZ, MEK, AFS, KD, UL, CWe, WK, DR, UM, LPB, HB, RTJ, STri, MKI, SB, CS, RBS, KJL, ON, GFTS, GST, JS, RL, NS, JWJ, GD, TSt, APP, VAC, AMR, RND, RC-D, JJ, MSc, FB, JT, JGS, RM, SC, JAS, OO, DG, NM, AL, CHS, HD, AM, PSB, CPN, NJS, IEH, GP, AAQ, Y-AK, JAH, HA, WHWT, SLH, CH, EH, AFRS, AS, LW, AA, IK, CL, LP, JCE, JMB, PB, WS, MKa, MSa, SSV, CMB, V-VL, EB, BDH, AH, FWA, HS, WM, and TSp collected data. SZ, MEK, ROM, AFS, KD, CWe, DR, UM, HB, RTJ, IP, STri, MKI, AF, CWa, CS, EV, ON, ERP, GST, JS, RL, STro RAJS, NS, HVG, GD, TSt, VAC, YG, MSc, FB, JT, JGS, ROV, SC, PAL, OO, DG, NM, AL, CHS, HD, AM, PSB, CPN, NJS, DK, AAQ, Y-AK, JAH, HA, SLH, NE, CH, CL, LP, JCE, JMB, GT, PB, WS, MKa, MSa, SSV, V-VL, EB, BDH, AH, FWA, HS, DF, and TSp analysed the data. SZ, MEK, ROM, AFS, KD, UL, WK, DR, UM, LPB, HB, RTJ, IP, STri, MKI, CS, RBS, ON, ERP, GST, NS, RL, TStro, RAJS, NS, JWJ, GD, VAC, YG, RC-D, JJ, MSc, JT, SC, CPN, NJS, AAQ, Y-AK, JAH, HA, SLH, CH, EH, LW, AA, CL, LP, JCE, JMB, GT, PB, MKa, V-VL, EB, MVH, BDH, AH, FWA, BKK, HS, DF, WM, and TSp interpreted the data. SZ, MEK, WK, UL, MKI, GD, YG, RC-D, JJ, AA, AH, FWA, RSP, BKK, DF, WM, and TSp wrote the paper. SZ, MEK, ROM, AFS, KD, CWe, DR, UM, LPB, HB, RTJ, IP, STri, MKI, AF, CS, ON, GST, GFTS, ERP, MSN, STro, RAJS, NS, JWJ, HVG, GD, APP, VAC, AMR, RND, MCs, JT, RM, SC, JAS, OO, DG, NM, CPN, NJS, JAH, AAQ, Y-AK, WHWT, SLH, CH, LW, AA, AS, CL, LP, JCE, JMB, GT, PB, WS, MKa, MSa, SSV, CMB, V-VL, EB, MVH, BDH, AH, FWA, RSP, HS, DF, and TSp provided critical revision of the drafts. RSP coordinated data collection and analysis for the GENIUS-CHD consortium. VT was the main analyst of GENIUS-CHD and gathered, processed, pooled, and produced outputs with the data obtained from the GENIUS-CHD cohorts.

Declaration of interests

The other authors declare that they have no competing interests.

associations were replicated through large-scale collaborative analysis in the GENIUS-CHD consortium, comprising 106 353 patients with established coronary heart disease and 19 332 deaths in 22 studies or cohorts.

Findings—The median follow-up was 9.9 years. Increased severity of coronary heart disease was associated with lipoprotein(a) concentrations in plasma in the highest tertile (adjusted hazard ratio [HR] 1.44, 95% CI 1.14–1.83) and the presence of either *LPA* SNP (1.88, 1.40–2.53). No associations were found in LURIC with all-cause mortality (highest tertile of lipoprotein(a) concentration in plasma 0.95, 0.81–1.11 and either *LPA* SNP 1.10, 0.92–1.31) or cardiovascular mortality (0.99, 0.81–1.2 and 1.13, 0.90–1.40, respectively) or in the validation studies.

Interpretation—In patients with prevalent coronary heart disease, lipoprotein(a) concentrations and genetic variants showed no associations with mortality. We conclude that these variables are not useful risk factors to measure to predict progression to death after coronary heart disease is established.

Funding—Seventh Framework Programme for Research and Technical Development (AtheroRemo and RiskyCAD), INTERREG IV Oberrhein Programme, Deutsche Nierenstiftung, Else-Kroener Fresenius Foundation, Deutsche Stiftung für Herzforschung, Deutsche Forschungsgemeinschaft, Saarland University, German Federal Ministry of Education and Research, Willy Robert Pitzer Foundation, and Waldburg-Zeil Clinics Isny.

Introduction

Worldwide, cardiovascular disease remains the leading cause of death.¹ Lipoprotein(a) has been identified as a risk factor for cardiovascular disease and suggested as a potential therapeutic target based on independent associations with atherosclerosis and cardiovascular events in general population studies.^{2,3} A meta-analysis of 18 general population studies showed a combined risk ratio for coronary heart disease of 1.7 (95% CI 1.4–1.9) for people with lipoprotein(a) concentrations in the highest tertile compared with those who had concentrations in the lowest tertile.⁴ The Copenhagen City Heart Study⁵ showed a very similar risk estimate when comparing tertiles, and even higher risks once lipoprotein(a) concentrations exceeded the 90th percentile of the frequency distribution. In an individual-level meta-analysis of patients' records, participants with a history of cardiovascular disease at baseline were excluded.⁶ A continuous, although modest, relation between lipoprotein(a) concentrations and the incidence of coronary heart disease and stroke was found in this general population, with frequencies of events per 1000 person-years being 5.6 (95% CI 5.4–5.9) and 4.4 (4.2–4.6) in the highest and lowest tertiles of lipoprotein(a) concentrations, respectively.

Lipoprotein(a) is composed of an LDL-like core containing apolipoprotein B, to which one copy of the apolipoprotein(a) glycoprotein is attached by a disulfide bridge.^{7–9} The physiological function of lipoprotein(a) is unknown, as are the precise mechanisms of synthesis and catabolism. Assembly is thought to be on the surface membrane of hepatocytes,¹⁰ and several cell-surface receptors have been implicated in its catabolism.¹¹ Lipoprotein(a) might have effects on the vascular tree similar to those of LDL, but it is postulated to be more atherogenic because of specific prothrombotic effects.³ Circulating

concentrations of lipoprotein(a) vary widely and are related to the number of kringle IV type 2 repeats and other sequence variants in the *LPA* gene.^{12,13} Two common *LPA* single-nucleotide polymorphisms (SNPs), rs10455872 (intronic non-coding) and rs3798220 (missense variant Ile4399Met in the apolipoprotein(a) protease-like domain), explain much of the variation in lipoprotein(a) concentrations, and are linked to the risk of incident myocardial infarction.^{14,15}

Unlike many other traditional risk factors for coronary heart disease, lipoprotein(a) is difficult to modify by lifestyle changes.³ PCSK9 inhibitors reduce concentrations of lipoprotein(a) by 20–30%,¹⁶ but are not yet routinely used for this purpose. Lipoprotein apheresis is the only available approach to substantially lower lipoprotein(a) concentrations.³

The relation between increased lipoprotein(a) concentrations and future or recurrent cardiac events in patients with established coronary heart disease has been less extensively studied than the relation in people in the general population, but so far seems weaker. Furthermore, risk might be modified by LDL-cholesterol concentration.^{4,17,18} We aimed to assess systematically whether lipoprotein(a) and two *LPA* SNPs are associated with long-term mortality and disease severity in a large population of patients with established coronary heart disease.

Methods

Patients

Between 1997 and 2000, 3313 German patients scheduled to undergo coronary angiography were enrolled in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study.¹⁹ The study design and examinations at baseline have been described elsewhere.¹⁹ Participants with acute illnesses other than acute coronary syndromes, such as malignancy or other chronic non-cardiac diseases, within the previous 5 years were excluded. Clinically stable patients without acute coronary syndromes who had coronary angiogram data were enrolled. Information on death during follow-up was obtained from the local public health departments. Cardiovascular mortality was defined as death due to fatal myocardial infarction, sudden cardiac death, death after cardiovascular intervention, stroke, and other deaths caused by cardiovascular diseases.

The study was done in accordance with the Declaration of Helsinki and approved by the responsible ethics committee of Ärztekammer Rhineland-Palatinate, Germany. Written informed consent was obtained from all patients. No patients were lost to follow-up.

Lipoprotein(a) validation cohorts

We compared our findings for associations with lipoprotein(a) concentrations in plasma with those from 10 195 participants in five independent prospective studies: the Homburg Cream and Sugar (HCS) study, the KAROLA study, the WENBIT/WECAC study, the PROSPER study, and the ATHEROGENE study (appendix pp 1–3). These studies were selected because of good matches for inclusion criteria and comparable cardiovascular endpoints available. Following the strategy of a previous meta-analysis,⁴ we separated lipoprotein(a) concentrations into tertiles to minimise the effects of different methods of measurement.

Genetic associations

Positive *LPA* SNP carrier status was defined as heterozygosity or homozygosity for the minor alleles of rs10455872, rs3798220, or both. Associations for the two *LPA* SNPs with all-cause and cardiovascular mortality from LURIC were validated by collaborative analysis through the Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium at the individual participant level.²⁰ This grouping of multiple international studies brings together data from patients with coronary heart disease, including stable disease and acute coronary syndromes, who have blood or tissue samples stored for analysis or genotyping data, and prospective follow-up data for subsequent events, including cardiovascular events and death. We compared our genetic findings with those in studies and cohorts with available data for *LPA* SNP (appendix p 1).

Laboratory methods and procedures

In LURIC, blood samples were taken on the day of coronary angiography for measurement of lipoprotein(a) concentrations in plasma with the LPA Test (Rolf Greiner Biochimica, Flacht, Germany). Details of laboratory methods for the other studies and cohorts are described in the appendix (pp 3–5).

Statistical analysis

Continuous data are presented as means and SDs when normally distributed or as medians and IQRs for variables with skewed distributions. Categorical data are presented as numbers and percentages. Statistical differences between continuous variables were determined with one-way ANOVA, and between categorical variables with the Kruskal-Wallis test or the χ^2 test. In analyses of the associations, models were analysed with and without adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate (eGFR), and LDL-cholesterol concentration.

Associations between tertiles of lipoprotein(a) concentrations in plasma and *LPA* SNP carrier status with all-cause and cardiovascular mortality in the LURIC study were assessed with Cox regression analyses. We did sensitivity analyses to determine the association between lipoprotein(a) concentrations in plasma and mortality in patients receiving statins or no statins and for those with LDL-cholesterol concentrations of 130 mg/dL or less versus more than 130 mg/dL. Moreover, to assess the degree of variance in lipoprotein(a) concentrations caused by the *LPA* SNPs rs10455872 and rs3798220, we calculated η^2 . Associations between tertiles of lipoprotein(a) and *LPA* SNP carrier status and risk of coronary heart disease or severity of coronary heart disease were assessed with logistic regression analyses or linear regression analyses, respectively.

In the lipoprotein(a) concentration validation studies, we also used Cox regression analyses to assess the association between tertiles of lipoprotein(a) and each study's composite cardiovascular endpoints. To analyse the association between the two *LPA* SNPs and cardiovascular outcome in the GENIUS-CHD consortium, we did meta-analyses with log hazard ratios (HRs) and SEs derived from unadjusted Cox regression models of the association between the SNPs and fatal cardiovascular events and all-cause mortality from every cohort included. Standard normal random-effects meta-analysis was done with the R

metaplas package (version 0.7–8). All other analyses were done with SPSS version 20.0. Data are presented as HRs or odds ratios (ORs) with 95% CIs.

We assessed associations between the different tertiles of lipoprotein(a) concentration or *LPA* SNP carrier status and Friesinger score as a measure for the severity of coronary heart disease in LURIC. We used generalised linear models to estimate the marginal means of Friesinger score and made adjustments for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, eGFR, LDL-cholesterol concentration, and the use of lipid-lowering therapy.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

3313 participants in the LURIC study with established coronary heart disease, lipoprotein(a) measurements, and genotyping data were included in these analyses (table). 10 195 patients were included in the five independent studies of cardiovascular mortality and lipoprotein(a) concentrations in plasma (appendix pp 10–14), and data were available for 106 353 patients with established coronary heart disease and 19 332 deaths in 22 studies or cohorts from the GENIUS-CHD consortium (appendix pp 21–22).

The prevalence of most traditional cardiovascular risk factors (age, reduced eGFR, diabetes type 1 and type 2, smoking, and hypertension) among participants in the LURIC study did not differ significantly across tertiles of lipoprotein(a) concentration. Significant differences were noted for LDL-cholesterol concentration and distribution of male or female sex. The prevalence of coronary heart disease at baseline was 78%. Among patients with lipoprotein(a) concentrations in the highest tertile, the prevalence of angiographically defined coronary heart disease was significantly greater than among those with concentrations in the lowest tertile (table).

Among participants in LURIC, data on rs10455872 were available for 3058 and on rs3798220 for 3286. 524 (16%) participants carried any minor allele, of whom ten carried minor alleles in both SNPs (table). The frequencies of minor alleles increased with increasing tertile of lipoprotein(a) concentration (table). Of note, we saw an almost linear increase in the number of minor alleles with increasing median concentration of lipoprotein(a) in plasma ($p < 0.0001$), and for each *LPA* SNP minor allele carried the median lipoprotein(a) concentration was increased by 250% (appendix p 23).

Compared with patients who had lipoprotein(a) concentrations in the lowest tertile, the risk for angiographic coronary heart disease in the LURIC study was significantly increased for those with concentrations in the highest tertile (adjusted HR 1.44, 95% CI 1.14–1.83; figure 1, appendix p 7). Similar results were obtained for carriers of any *LPA* SNP (adjusted OR 1.88, 95% CI 1.40–2.53 appendix p 6). Increased concentrations of lipoprotein(a) in plasma

and being a carrier of one or more *LPA* SNP minor alleles were associated with increased severity of coronary heart disease (figure 1).

During a median follow-up of 9.9 years, 994 (30%) patients in the LURIC study died. 621 (19%) deaths were classified as cardiovascular disease-related deaths. We found no association between all-cause or cardiovascular mortality and any tertile of lipoprotein(a) concentration, in the crude or adjusted models (figure 2, appendix p 8). In our sensitivity analyses, this association was not modified by LDL-cholesterol concentration or statin treatment (appendix p 9).

In the five independent studies of cardiovascular mortality and lipoprotein(a) concentrations in plasma, no associations were found between tertiles of lipoprotein(a) concentrations and the composite cardiovascular endpoints or cardiovascular mortality (figure 2, appendix pp 15–19).

We found no association between *LPA* SNPs and all-cause or cardiovascular mortality in LURIC (figure 2, appendix p 20). Likewise, in the validation studies and cohorts from the GENIUS-CHD consortium, neither rs10455872 nor rs3798220 was associated with increased all-cause or cardiovascular mortality (figure 3).

Discussion

Among patients in the LURIC study with established coronary heart disease, the concentration of lipoprotein(a) in plasma at the time of recruitment and the number of minor alleles at two biallelic SNPs in *LPA* loci were positively related to the presence and severity of coronary heart disease, which supports findings in previous case-control or cross-sectional studies involving patients with or without prevalent cardiovascular disease.^{14,21,22} By contrast, neither lipoprotein(a) concentrations nor *LPA* SNPs were associated with cardiovascular or all-cause mortality during long-term follow-up. These findings were validated in 27 studies and cohorts that included 116 548 participants.

The association between lipoprotein(a) and coronary heart disease, which is independent of traditional cardiovascular risk factors, has been known for many years.^{4–6,23–25} It is based on findings mainly from studies of apparently healthy participants in the general population^{4–6,25} rather than from investigations of patients with established coronary heart disease. Genetic diversity at the *LPA* locus, including the SNPs rs10455872 and rs3798220, has been associated with raised concentrations of lipoprotein(a) in plasma and incident cardiovascular disease.^{6,14} *LPA* kringle IV type 2 repeats and raised lipoprotein(a) concentrations in serum have been associated with increased prevalence of coronary heart disease in a mendelian randomisation analysis.²⁶ The findings from previous studies and this analysis, therefore, support a causal link between lipoprotein(a) and atherosclerosis development.

The lack of a clear association between lipoprotein(a) concentrations or *LPA* variants and mortality in the LURIC population or in the 27 validation studies and cohorts raises the possibility that lipoprotein(a) concentration is a weaker risk factor in patients with coronary heart disease than in healthy people. This difference might be due to competing risks

commonly seen in patients. In a meta-analysis, the risk ratio for coronary heart disease in the general population was 1.7 (95% CI 1.4–1.9) when the highest and lowest tertiles of lipoprotein(a) concentrations were compared, but was only 1.3 (1.1–1.6) for patients who had pre-existing comorbidities in nine studies (two of patients receiving dialysis, one of patients with diabetes, and six of patients with coronary heart disease).⁴ Of note, however, the largest contributor of patients with comorbidities to that meta-analysis was the Scandinavian Simvastatin Survival Study,²⁷ which included patients with severe hypercholesterolaemia. These patients were not representative of the wider coronary heart disease population, having total cholesterol concentrations in the range of 212–309 mg/dL, but accounted for three-quarters of the comorbidity evidence in the meta-analysis. These total cholesterol concentrations are much higher than those in LURIC and the GENIUS-CHD populations. Generalisability of the findings of the meta-analysis to people with lower total cholesterol concentrations is, therefore, limited. Of the eight remaining studies in the meta-analysis, only one reported a significant association between lipoprotein(a) and incident coronary heart disease.

A study of patients with established coronary heart disease showed a small but non-significant relation between lipoprotein(a) and future cardiovascular events among those with mean concentrations of LDL cholesterol higher than 130 mg/dL at baseline compared with patients who had lower concentrations.¹⁷ The association between lipoprotein(a) concentration and cardiovascular events might, therefore, be modified by LDL-cholesterol concentration, and, beyond this, potentially by statin use. We did not detect such interactions in our analyses, but in LURIC the mean LDL-cholesterol concentration was 117 (SD 34) mg/dL at baseline, and in the GENIUS-CHD consortium studies the value was 130 (38) mg/dL. As such, we could not investigate an association between lipoprotein(a) and cardiovascular outcomes in patients with very high LDL-cholesterol concentrations. Adjustments for other established confounders investigated at baseline (age, sex, diabetes, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy) also did not modify our findings, although we could not account for factors that might have changed during follow-up, such as LDL-cholesterol concentration. In Germany, however, adherence to statin regimens is poor and we suspect that an effect of time-dependent changes in LDL-cholesterol concentrations is unlikely, at least in the German cohorts included in our analysis.²⁸

Our analysis had other limitations that should be taken into account. First, lipoprotein(a) concentrations in plasma were measured by different methods in LURIC and the validation cohorts. To minimise bias caused by differences in assay calibrations, we assessed all risk estimates in relation to tertiles of lipoprotein(a) concentrations. Nevertheless, we cannot entirely exclude the possibility that lipoprotein(a) concentrations in plasma were altered by the initial cardiovascular event itself or by changes during follow-up. Second, we focused only on all-cause and cardiovascular mortality, but other studies have combined various fatal and non-fatal cardiovascular events.^{4–6,17} Exclusion of non-fatal events arguably keeps to a minimum the effects of differences between studies and changes over time in definitions and methods of assessment.²⁹ This approach might have reduced the statistical power to detect differences between populations due to the number of events being reduced, meaning we

could have missed small effect sizes. A type 2 error remains possible, but, owing to the sample size afforded by the use of independent study cohorts, we anticipate this risk to be minimal. Nevertheless, we cannot rule out that extreme concentrations of lipoprotein(a) (ie, 50 mg/dL), beyond which the recent European Society of Cardiology and European Atherosclerosis guideline deems risk to be high,³⁰ would have effects. Finally, we could not compare effects of lipoprotein(a) concentrations or genetic variants on risk of subsequent non-fatal events with those on fatal events, which could have been of interest given that such differences have been described for other risk factors.³¹ Ischaemic events, thrombotic events, or both—fatal and non-fatal—might be more specifically related to lipoprotein(a) than cardiovascular deaths overall. These relations will need to be studied further as outcome data emerge, particularly since lipoprotein(a) concentrations seemed in previous analyses to have similar associations with fatal coronary heart disease and non-fatal myocardial infarction in patients without established coronary heart disease.⁶

The results from this and previous studies suggest that lipoprotein(a) concentrations and *LPA* SNPs promote early development of atherosclerosis and severe coronary heart disease. Furthermore, patients with established coronary heart disease who carry SNPs associated with increased concentrations of lipoprotein(a) are more likely to have earlier onset of disease and be more susceptible to atherosclerotic manifestations outside of the coronary tree than patients without SNPs,²¹ which supports a role of lipoprotein(a) in atherosclerosis progression. The lack of association between lipoprotein(a) and cardiovascular mortality in this study was surprising and is a finding that we cannot explain. Among the possible explanations are index event biases or survival biases. We cannot fully exclude these possibilities, although they are unlikely to have affected our findings substantially because the frequencies of *LPA* SNP minor allele were the same in our and the control populations, and in the PROCARDIS and other cohorts.¹⁴ Additionally, the characteristics of patients were well balanced across genotypes. Of note, although lipoprotein(a) concentrations would not be useful for predicting mortality, patients with coronary heart disease and high lipoprotein(a) concentrations might still benefit from lipid-lowering treatment, as it might slow disease progression.

Screening for increased concentrations of lipoprotein(a) is recommended in people at intermediate or high risk of cardiovascular disease or coronary heart disease.³ In view of the broad evidence in favour of lipoprotein(a) as a marker of risk in clinically healthy people,^{3,24} our data suggest that integration of lipoprotein(a) into risk stratification in primary rather than in secondary prevention might be more useful. We acknowledge that detection of very high concentrations of lipoprotein(a) in plasma in patients with established coronary heart disease could be helpful to trigger screening of family members to improve early preventive measures for carriers of *LPA* genetic variants.

Interventions that lower concentrations of lipoprotein(a) are scarce. Additionally, whether lowering of lipoprotein(a) concentrations by drugs such as PCSK9 inhibitors has an added effect on cardiovascular outcomes beyond that mediated by their substantial reductions of LDL-cholesterol concentrations needs to be determined.¹⁶ More specific therapies targeting lipoprotein(a) directly, such as antisense oligonucleotides, are being developed and tested,³²

and findings of these studies might make clearer the usefulness of reducing lipoprotein(a) concentrations.

Concentrations of lipoprotein(a) in plasma and genetic variants were strongly associated with the presence and severity of coronary heart disease, but neither predicted the risk of cardiovascular or all-cause mortality in patients with established disease. Although the discrepancy in these findings with those in general populations, where lipoprotein(a) increases risk of a first coronary heart disease event, requires further investigation, our data suggest that use of lipoprotein(a) as a risk marker might be useful to predict onset of coronary heart disease rather than progression to death after a coronary heart disease event.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Stephen Zewinger, Marcus E Kleber, Vinicius Tragante, Raymond O McCubrey, Amand F Schmidt, Kenan Direk, Ulrich Laufs, Christian Werner, Wolfgang Koenig, Dietrich Rothenbacher, Ute Mons, Lutz P Breitling, Herrmann Brenner, Richard T Jennings, Ioannis Petrakis, Sarah Triem, Mira Klug, Alexandra Filips, Stefan Blankenberg, Christoph Waldeyer, Christoph Sinning, Renate B Schnabel, Karl J Lackner, Efthymia Vlachopoulou, Ottar Nygård, Gard Frodahl Tveitevåg Svingen, Eva Ringdal Pedersen, Grethe S Tell, Juha Sinisalo, Markku S Nieminen, Reijo Laaksonen, Stella Trompet, Roelof A J Smit, Naveed Sattar, J Wouter Jukema, Heinrich V Groesdonk, Graciela Delgado, Tatjana Stojakovic, Anna P Pilbrow, Vicky A Cameron, A Mark Richards, Robert N Doughty, Yan Gong, Rhonda Cooper-DeHoff, Julie Johnson, Markus Scholz, Frank Beutner, Joachim Thiery, J Gustav Smith, Ragnar O Vilmundarson, Ruth McPherson, Alexandre F R Stewart, Sharon Cresci, Petra A Lenzini, John A Spertus, Oliviero Olivieri, Domenico Girelli, Nicola I Martinelli, Andreas Leihner, Christoph H Saely, Heinz Drexel, Axel Mündlein, Peter S Braund, Christopher P Nelson, Nilesh J Samani, Daniel Kofink, Imo E Hoefler, Gerard Pasterkamp, Arshed A Quyyumi, Yi-An Ko, Jaana A Hartiala, Hooman Allayee, W H Wilson Tang, Stanley L Hazen, Niclas Eriksson, Claes Held, Emil Hagström, Lars Wallentin, Axel Åkerblom, Agneta Siegbahn, Igor Karp, Christopher Labos, Louise Pilote, James C Engert, James M Brophy, George Thanassoulis, Peter Bogaty, Wojciech Szczeklik, Marcin Kaczor, Marek Sanak, Salim S Virani, Christie M Ballantyne, Vei-Vei Lee, Eric Boerwinkle, Michael V Holmes, Benjamin D Horne, Aroon Hingorani, Folkert W Asselbergs, Riyaz S Patel **on behalf of the GENIUS-CHD consortium**, Bernhard K Krämer, Hubert Scharnagl, Danilo Fliser, Winfried März*, and Thimoteus Speer*

Affiliations

Department of Internal Medicine IV (S Zewinger MD, R T Jennings PhD, I Petrakis MD, S Triem MSc, M Klug MSc, A Filips MD, Prof D Fliser MD, T Speer MD), Department of Internal Medicine III (Prof U Laufs MD, C Werner MD), and

Department of Anesthesiology, Intensive Care Medicine, and Pain Medicine (H V Groesdonk MD), Saarland University Hospital, Homburg/ Saar, Germany; Fifth Department of Medicine (M E Kleber PhD, G Delgado MSc, Prof W März MD, Prof B K Krämer MD) and Network Ageing Research (Prof H Brenner MD), University Heidelberg, Mannheim, Germany; Institute of Nutrition, Friedrich-Schiller University, Jena, Germany (M E Kleber); Department of Cardiology, Heart and Lungs Division (V Tragante PhD, Prof F W Asselbergs MD, D Kofink MD) and Laboratory of Experimental Cardiology (I E Hoefler MD, Prof G Pasterkamp PhD), UMC Utrecht, Utrecht, Netherlands; Intermountain Heart Institute, Intermountain Medical Center, University of Utah School of Medicine, Salt Lake City, UT, USA (R O McCubrey MS, B D Horne PhD); Institute of Cardiovascular Science Faculty of Population Health Science, University College London, London, UK (A F Schmidt MPH, K Direk MD, Prof A Hingorani MD, R S Patel MD, Prof F W Asselbergs); Department of Internal Medicine II–Cardiology, University of Ulm Medical Centre, Ulm, Germany (W Koenig MD); Deutsches Herzzentrum München, Technische Universität München, Munich, Germany (W Koenig); German Centre of Cardiovascular Research (DZHK), Partner site Munich Heart Alliance, Munich, Germany (W Koenig); Division of Clinical Epidemiology and Ageing Research, German Cancer Centre (DKFZ), Heidelberg, Germany (Prof D Rothenbacher MD, U Mons PD, L P Breitling MD, Prof H Brenner); Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany (Prof D Rothenbacher); University Heart Centre Hamburg, Clinic for General and Interventional Cardiology, Hamburg, Germany (Prof S Blankenberg MD, C Waldeyer MD, C Sinning MD, R B Schnabel MD); German Centre for Cardiovascular Research (DZHK e.V.), partner site Hamburg/Kiel/Lübeck, Germany (Prof S Blankenberg, C Waldeyer, C Sinning, R B Schnabel); Institute of Clinical Chemistry and Laboratory Medicine, University Medical Centre Mainz, Germany (Prof K L Lackner MD); Transplantation Laboratory, Haartman Institute, University of Helsinki, Finland (E Vlachopoulou PhD); Department of Clinical Science (Prof O Nygård MD, E Ringdal Pedersen MD) and Department of Global Public Health and Primary Care (Prof G S Tell PhD), University of Bergen, Bergen, Norway; Department of Heart Disease, Haukeland University Hospital, Bergen, Norway (O Nygård, G F Tveitevåg Svingen MD); Heart and Lung Centre, Helsinki University Hospital, Helsinki, Finland (Prof J Sinisalo MD, Prof M S Nieminen PhD); Medical School, Tampere University, Tampere, Finland (Prof R Laaksonen MD); Finnish Clinical Biobank Tampere, University Hospital of Tampere, Tampere, Finland (Prof R Laaksonen); Department of Geriatrics and Gerontology (S Trompet PhD, R A J Smit MD), Department of Cardiology (S Trompet, R A J Smit), and Einthoven Laboratory for Experimental Vascular Medicine (Prof J Wouter Jukema MD), Leiden University Medical Centre, Leiden, Netherlands; Institute of Cardiovascular and Medical Science, BHF Glasgow, Cardiovascular Research Centre, University of Glasgow, Glasgow, UK (Prof N Sattar FMedSci); Interuniversity Cardiology Institute of the Netherlands, Utrecht, Netherlands (J Wouter Jukema); Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria (T Stojakovic MD, J Scharnagl PhD, Prof W März); Christchurch Heart Institute, University of Otago, Christchurch, New Zealand (A P Pilbrow PhD, Prof V A Cameron PhD, Prof A M

Richards MD); Cardiovascular Research Institute, National University of Singapore, Singapore (Prof A M Richards); Heart Health Research Group, University of Auckland, New Zealand (Prof R N Doughty MD); Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, Colleges of Pharmacy, University of Florida, Gainesville, FL, USA (Y Gong PhD, R Cooper-DeHoff PharmD, Prof J Johnson PharmD); Institute for Medical Informatics, Statistics and Epidemiology (Prof M Scholz PhD) and LIFE Research Centre for Civilisation Diseases (Prof M Scholz, Prof J Thiery MD), University of Leipzig, Leipzig, Germany; Heart Centre Leipzig, Leipzig, Germany (F Beutner MD); Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital, Leipzig, Germany (Prof J Thiery); Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden (J G Smith MD); Skåne University Hospital, Lund, Sweden (J G Smith); Ruddy Canadian Cardiovascular Genetics Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada (R O Vilmundarson MSc, Prof R McPherson MD, Prof A F R Stewart PhD); Department of Medicine (S Cresci MD), Department of Genetics (S Cresci), and Statistical Genomics Division, Department of Genetics (P A Lenzini PhD), Washington University School of Medicine, Saint Louis, MO, USA; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA (Prof J A Spertus MD); Department of Biomedical and Health Informatics, University of Missouri-Kansas City, Kansas City, MO, USA (Prof J A Spertus); Department of Medicine, University of Verona, Verona, Italy (Prof O Olivieri MD, Prof D Girelli MD, N I Martinelli MD); Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria (A Leiberer PhD, Prof C H Saely MD, Prof H Drexel MD, A Mündlein PhD); Private University of the Principality of Liechtenstein, Triesen, Liechtenstein (A Leiberer, Prof C H Saely, Prof H Drexel); Department of Medicine and Cardiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria (Prof H Drexel); Drexel University College of Medicine, Philadelphia, PA, USA (Prof H Drexel); Department of Cardiovascular Sciences, University of Leicester, BHF Cardiovascular Research Centre, Glenfield Hospital, Leicester, UK (Prof P S Braund PhD, C P Nelson PhD, Prof N J Samani MD); Leicester NIHR Biomedical Research Unit in Cardiovascular Disease, Glenfield Hospital, Leicester, UK (Prof P S Braund, C P Nelson, Prof N J Samani); Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, USA (Prof A A Quyyumi MD, Y-A Ko PhD); University of Southern California, Los Angeles, CA, USA (J A Hartiala PhD, Prof H Allayee PhD); Cleveland Clinic, Cleveland, OH, USA (W H Wilson Tang MD, Prof S L Hazen MD); Uppsala Clinical Research Centre (N Eriksson PhD, C Held MD, E Hagström MD, Prof L Wallentin MD, A Åkerblom MD, Prof A Siegbahn MD), Department of Medical Sciences, Cardiology (N Eriksson, C Held, E Hagström, Prof L Wallentin, A Åkerblom), and Department of Medical Sciences, Clinical Chemistry (Prof A Siegbahn), Uppsala University, Uppsala, Sweden; University of Montreal Hospital Research Centre (CRCHUM) (I Karp PhD) and Department of Social and Preventive Medicine (I Karp), University of Montreal, Montreal, QC, Canada; Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada (I Karp); Department

of Medicine, McGill University, Montreal, QC, Canada (C Labos MD, Prof L Pilote MD, J C Engert PhD, Prof J M Brophy MD, G Thanassoulis MD); Division of General Internal Medicine (Prof L Pilote) and Division of Clinical Epidemiology (Prof L Pilote), McGill University Health Centre, Montreal, QC, Canada; Department of Medicine, Université Laval, QC, Canada (Prof P Bogaty MD); Jagielonian University Medical College, Kraków, Poland (Prof W Szczeklik MD, M Kaczor MD, Prof M Sanak MD); Section of Cardiology, Michael E DeBakey Veterans Affairs Medical Center (S S Virani MD) and Section of Cardiovascular Research, Department of Medicine (Prof C M Ballantyne MD), Baylor College of Medicine, Houston, TX, USA; Department of Biostatistics 7, Epidemiology, Texas Heart Institute, Houston, TX, USA (V-V Lee MD); School of Public Health, University of Texas, Houston, TX, USA (Prof E Boerwinkle PhD); Medical Research Council Population Health Research Unit at the University of Oxford (M V Holmes PhD), Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health (M V Holmes), University of Oxford, Oxford, UK; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, UK (M V Holmes); Durrer Centre of Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, Netherlands (Prof F W Asselbergs); and Synlab Academy, Synlab Holding, Mannheim, Germany (Prof W März)

Acknowledgments

FWA is supported by Dekker scholarship-Junior Staff Member 2014T001—Netherlands Heart Foundation and UCL Hospitals National Institute for Health Research (NIHR) Biomedical Research Centre. GeneBank was supported in part by grants P01HL098055, P01HL076491, and R01HL103931 from the National Institutes for Health (NIH). SLH is supported by a gift from the Leonard Krieger Fund. INVEST Genes, a member of the Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium, was supported by the University of Florida and grants from Abbott Laboratories and BASF Pharma. INVEST Genes, a member of GENIUS-CHD did a genetic substudy supported by Abbott Laboratories, the NIH Pharmacogenetics Research Network (grant U01-GM074492), NIH (R01 HL074730), and UF Opportunity Fund and genome-wide genotyping and imputation, which were done by the RIKEN Centre for Integrative Medical Sciences, Yokohama, Japan. The Krakow GENIUS-CHD cohort was supported by a grant from the National Science Centre (2013/09/B/NZ5/00770) and the Polish Ministry of Science and Higher Education (NN402083939). LIFE-Heart, a member of the GENIUS-CHD consortium, is supported by the European Union, European Regional Development Fund (ERDF), and the Free State of Saxony within the framework of the excellence initiative, and LIFE–Leipzig Research Centre for Civilization Diseases. We thank the patients, their families, and the physicians involved in the study by the GENIUS-CHD consortium member, TexGen. SC is supported by the NIH (Cresci R01 NR013396). The TRIUMPH GENIUS-CHD study was sponsored by the NIH via a grant given to the Washington University School of Medicine (SCCOR Grant P50 HL077113). VHS was supported by the Cariverona Foundation, Verona, Italy. GT is supported by a Fonds de la Recherche en Santé du Québec (FRQS) Chercheur Boursier Clinicien Salary Award. This study was supported by the Canadian Institutes of Health Research ([CIHR] CIHR MOP-119380 and HSFC G-15-0009339 awarded to GT and CIHR IGO-86113 awarded to IP). The RISCA GENIUS-CHD cohort was supported in part by the FRQS, the Heart and Stroke Foundation of Canada, and unrestricted grants from Merck Frosst Canada and Pfizer Canada. The PRAXY GENIUS-CHD cohort was supported by the CIHR and the Heart and Stroke Foundations of Quebec, Nova Scotia, Alberta, Ontario, Yukon, and British Columbia (MOP-89369). The AtheroGene study is supported by the Fondation de France (no. 2002004994), the French Ministry of Research (ACI IMPBIO 032619), Institut National de la Santé et de la Recherche Médicale (Programme National de Recherches sur les Maladies Cardiovasculaires A04052DS), the MAIFOR grant 2001 of the Johannes Gutenberg-University Mainz, and a grant of the Stiftung Rheinland-Pfalz für Innovation, Ministry of Science and Education (AZ 15202–386261/545). The KAROLA study was supported by the German Federal Ministry of Education and Research (01GD9820/0, 01ER0814), by the Willy Robert Pitzer Foundation, and Waldburg-Zeil Clinics Isny. The AtheroGene study is part of the European collaborative research project Biomarker for Cardiovascular Risk Assessment in Europe, which is supported by the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement number HEALTH-F2-2011-278913 (BiomarCaRE). NS is supported by the British Heart Foundation and is an NIHR Senior Investigator. RSP is supported by a British Heart Foundation fellowship (FS/14/76/30933). WENBIT/ BECAC has been funded by the Advanced Research Programme and Research Council of Norway, the Department of Heart Disease at Haukeland

University Hospital, the Norwegian Foundation for Health and Rehabilitation, the Norwegian Heart and Lung Patient Organisation, the Norwegian Ministry of Health and Care Services, and the Western Norway Regional Health Authority. We thank the deCODE collaborators for discussions and sharing of data from the deCODE study. SZ is supported by Deutsche Nierenstiftung and Else-Kroener Fresenius Stiftung. TSp is supported by Else-Kroener Fresenius Stiftung and Deutsche Forschungsgemeinschaft (DFG).

WK has received personal fees from Amgen, AstraZeneca, Berlin-Chemie, DaICor, GlaxoSmithKline, Kowa, Novartis, Pfizer, Sanofi, and The Medicines Company, and grants and non-financial support from Abbott, Beckmann, Roche Diagnostics, and Singulex. DR has received grants from the German Federal Ministry of Research and Education and Pitzer Foundation, and personal fees from MEDA, and Novartis. HB received grants for the KAROLA study from the German Federal Ministry of Education and Research (01GD9820/0, 01ER0814), the Willy Robert Pitzer Foundation, and by the Waldburg-Zeil Clinics. NS has received grants, personal fees, and other fees from Amgen. RC-D, MSc, and WHWT have received grants from the National Institutes of Health (NIH). MSc has received grants and personal fees from Merck Serono. NE has received grants from AstraZeneca and GlaxoSmithKline. CH has received grants from Bristol-Myers Squibb and GlaxoSmithKline and personal fees from AstraZeneca. EH has received grants from GlaxoSmithKline. LW has received institutional grants from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb GlaxoSmithKline, Merck, Pfizer, and Roche. AA has received grants from AstraZeneca and Roche Diagnostics. GT has received grants from Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, and Ionis Pharmaceuticals, and personal fees from Amgen, Ionis Pharmaceuticals, and Servier Canada. AH has received grants from the British Heart Foundation. FWA has received grants from the Dutch Heart Foundation. BKK has received grants from Astellas and Opsona, and personal fees from Astellas, Bayer, BMS, Chiesi, and Pfizer. WM has received grants from Abbott Diagnostics, grants and personal fees from Aegerion Pharmaceuticals, Amgen, Astrazeneca, BASF, Danone Research, Numares AG, Pfizer, Sanofi/Genzyme, and Siemens Diagnostics, and personal fees from Hoffmann LaRoche, MSD, Sanofi, Synageva, and other fees from Synlab Holding Deutschland.

References

1. Mozaffarian D, Benjamin EJ, et al. Writing Group M. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation*. 2016; 133:e38–60. [PubMed: 26673558]
2. Lamina C, Kronenberg F. The mysterious lipoprotein(a) is still good for a surprise. *Lancet Diabetes Endocrinol*. 2013; 1:170–72. [PubMed: 24622358]
3. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J*. 2010; 31:2844–53. [PubMed: 20965889]
4. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. *Circulation*. 2000; 102:1082–85. [PubMed: 10973834]
5. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. *Circulation*. 2008; 117:176–84. [PubMed: 18086931]
6. Erqou S, Kaptoge S, et al. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA*. 2009; 302:412–23. [PubMed: 19622820]
7. Utermann G. The mysteries of lipoprotein(a). *Science*. 1989; 246:904–10. [PubMed: 2530631]
8. Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. *Lancet Diabetes Endocrinol*. 2013; 1:220–27. [PubMed: 24622370]
9. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). *J Lipid Res*. 2016; 57:1339–59. [PubMed: 27074913]
10. White AL, Rainwater DL, Hixson JE, Estlack LE, Lanford RE. Intracellular processing of apo(a) in primary baboon hepatocytes. *Chem Phys Lipids*. 1994; 67–68:123–33.
11. Hoover-Plow J, Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. *Metabolism*. 2013; 62:479–91. [PubMed: 23040268]
12. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. *J Clin Invest*. 1992; 90:52–60. [PubMed: 1386087]

13. Schmidt K, Kraft HG, Parson W, Utermann G. Genetics of the Lp(a)/apo(a) system in an autochthonous Black African population from the Gabon. *Eur J Hum Genetics*. 2006; 14:190–201. [PubMed: 16267501]
14. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med*. 2009; 361:2518–28. [PubMed: 20032323]
15. Li J, Lange LA, Sabourin J, et al. Genome- and exome-wide association study of serum lipoprotein (a) in the Jackson Heart Study. *J Hum Genet*. 2015; 60:755–61. [PubMed: 26377243]
16. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *J Am Coll Cardiol*. 2014; 63:1278–88. [PubMed: 24509273]
17. O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. *J Am Coll Cardiol*. 2014; 63:520–27. [PubMed: 24161323]
18. Forbes CA, Quek RG, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review. *Lipids Health Dis*. 2016; 15:95. [PubMed: 27184891]
19. Winkelmann BR, März W, Boehm BO, et al. Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. *Pharmacogenomics*. 2001; 2(1 suppl 1):S1–73. [PubMed: 11258203]
20. Patel RS, Asselbergs FW. The GENIUS-CHD consortium. *Eur Heart J*. 2015; 36:2674–76. [PubMed: 26788565]
21. Helgadóttir A, Gretarsdóttir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. *J Am Coll Cardiol*. 2012; 60:722–29. [PubMed: 22898070]
22. Björnsson E, Gudbjartsson DF, Helgadóttir A, et al. Common sequence variants associated with coronary artery disease correlate with the extent of coronary atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2015; 35:1526–31. [PubMed: 25882067]
23. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici GB. Lipoprotein Lp(a) and the risk for myocardial infarction. *Atherosclerosis*. 1981; 38:51–61. [PubMed: 7470205]
24. Di Angelantonio E, Gao P, et al. Emerging Risk Factors C. Lipid-related markers and cardiovascular disease prediction. *JAMA*. 2012; 307:2499–506. [PubMed: 22797450]
25. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation*. 2014; 129:635–42. [PubMed: 24243886]
26. Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. *Lancet Diabetes Endocrinol*. 2017. published online April 10. [http://doi.org/10.1016/S2213-8587\(17\)30088-8](http://doi.org/10.1016/S2213-8587(17)30088-8)
27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994; 344:1383–89. [PubMed: 7968073]
28. Gitt AK, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. *Atherosclerosis*. 2016; 255:200–09. [PubMed: 27667299]
29. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2007; 28:2375–414. [PubMed: 17726041]
30. Catapano AL, Graham I, et al. Authors/Task Force M. 2016 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). *Atherosclerosis*. 2016; 253:281–344. [PubMed: 27594540]

31. Chan K, Patel RS, Newcombe P, et al. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. *J Am Coll Cardiol.* 2013; 61:957–70. [PubMed: 23352782]
32. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. *Lancet.* 2015; 386:1472–83. [PubMed: 26210642]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Research in context

Evidence before this study

Plasma lipoprotein(a) is a recognised emerging risk factor for coronary heart disease. We searched MEDLINE with the terms “lipoprotein(a)” and “lp(a)” to identify studies reporting on the association between lipoprotein(a) and cardiovascular risk published up to Dec 15, 2016. Several studies were identified that showed a clear association between increased concentrations of lipoprotein(a) in plasma and increased risk of atherosclerotic cardiovascular disease in general populations. In studies of patients with established coronary heart disease, however, the association was weak or absent, although populations were small and the studies were underpowered to assess this relation. Concentrations of lipoprotein(a) in plasma are genetically determined by two single-nucleotide polymorphisms (SNPs) in *LPA* loci (rs10455872 and rs3798220), which makes feasible exploration of the role of lipoprotein(a) in patients with coronary heart disease in large epidemiological and genetic association studies. Importantly, treatments for reducing lipoprotein(a) concentrations are also emerging. Thus, improved understanding of the role of lipoprotein(a) in this population would indicate whether lipoprotein(a) is likely to be a useful biomarker for risk stratification and treatment targets in patients with established coronary heart disease.

Added value of this study

We investigated whether lipoprotein(a) concentrations in plasma and two *LPA* SNPs were associated with long-term mortality and disease severity in patients with established coronary heart disease. Our findings were validated or replicated in 29 independent cohorts involving 116 548 participants with long-term follow-up. Neither lipoprotein(a) concentrations nor *LPA* genetic variants were associated with cardiovascular or all-cause mortality. However, concentrations of lipoprotein(a) in the highest tertile and the presence of either *LPA* SNP were associated with increased severity of coronary heart disease.

Implications of all the available evidence

Although observational data for measuring risk through stratification by lipoprotein(a) concentrations in general populations is robust, our findings raise questions about the usefulness of this biomarker in patients with established coronary heart disease. The reasons for this discrepancy need to be investigated. Treatments to reduce lipoprotein(a) concentrations are emerging, such as PCSK9 inhibitors and antisense agents, but whether lowering of lipoprotein(a) concentrations by drugs such as PCSK9 inhibitors has an added effect on cardiovascular outcomes beyond that mediated by their substantial reductions of LDL-cholesterol concentrations needs to be determined.




Figure 1. Association between tertiles of lipoprotein(a) concentrations or LPA SNP carrier status and presence and severity of coronary heart disease in the LURIC study

(A) Risk of coronary heart disease, presented as odds ratios and 95% CIs, as determined by logistic regression.

(B) Severity of coronary heart disease, presented as marginal means and 95% CIs. 3313 participants were assessed for the Lp(a) tertiles and 3287 for the LPA SNP analysis. All analyses were adjusted for age, sex, diabetes, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy. Lp(a)=lipoprotein(a). SNP=single-nucleotide polymorphism.




Figure 2. Association between tertiles of lipoprotein(a) concentration, LPA SNP carrier status, and mortality or cardiovascular endpoints

(A) All-cause and cardiovascular mortality in participants of the LURIC study. P values are for LPA SNP carrier yes vs no and for Lp(a) tertile 2 or 3 vs tertile 1. (B) Composite cardiovascular endpoints and cardiovascular mortality in validation studies. All values were calculated with Cox regression analysis adjusted for age, sex, diabetes, systolic blood pressure, BMI, smoking status, estimated glomerular filtration rate, LDL-cholesterol concentration, and use of lipid-lowering therapy. HR=hazard ratio. SNP=single-nucleotide polymorphism. Lp(a)=lipoprotein(a).




Figure 3. Forest plots of risk ratios for all-cause and cardiovascular mortality in studies of the GENIUS-CHD consortium

All-cause mortality associated with *LPA* single-nucleotide polymorphisms rs3798220 (A) and rs10455872 (B). Cardiovascular mortality associated with *LPA* SNPs rs3798220 (C) and rs10455872 (D). Markers represent point estimates of risk ratios and horizontal bars indicate 95% CIs. Marker size represents study weight in random-effects meta-analysis.

Table 1

Baseline characteristics of LURIC study participants

	All patients (n=3313)	Lp(a) tertile 1 10-0 mg/dL (n=1146)	Lp(a) tertile 2 10.1-26.0 mg/dL (n=1065)	Lp(a) tertile 3 >26.0 mg/dL (n=1102)	p value*
Age	62.7 (10.6)	62.8 (10.7)	62.8 (10.7)	62.4 (10.4)	0.445
Sex					
Male	2308 (70%)	842 (74%)	735 (69%)	731 (66.3%)	0.001
Female	1005 (30%)	304 (27%)	330 (31%)	371 (33.7%)	0.001
BMI (kg/m ²)	27.5 (4.1)	27.5 (4.1)	27.7 (4.2)	27.2 (3.9)	0.066
Systolic blood pressure (mm Hg)	141 (24)	142 (23)	140 (24)	141 (24)	0.184
Lipoprotein(a) concentration in plasma (mg/dL)	16.0 (0.5-31.5)	5.0 (1.8-8.2)	16.0 (12.5-19.6)	58.0 (35.7-80.4)	<0.0001
<i>LPA SNP minor alleles †</i>					
Any	524 (16%)	73 (6%)	81 (8%)	370 (34%)	<0.0001
rs10455872 A/G	399 (13%)	56 (5%)	63 (6%)	280 (28%)	<0.0001
rs10455872 G/G	10 (<0.5%)	0	1 (<0.5%)	9 (1%)	<0.0001
rs3798220 T/C	124 (3.8%)	17 (2%)	19 (2%)	88 (8%)	<0.0001
rs3798220 C/C	1 (<0.5%)	0	0	1 (<0.5%)	..
Lipid profile					
Total cholesterol (mg/dL)	192 (39)	189 (39)	191 (38)	197 (40)	<0.0001
Triglycerides (mg/dL)	173 (118)	179 (136)	173 (115)	167 (99)	0.089
HDL cholesterol (mg/dL)	39 (11)	38 (11)	39 (11)	39 (10)	0.037
LDL cholesterol (mg/dL)	117 (34)	112 (34)	116 (33)	122 (36)	<0.0001
VLDL cholesterol (mg/dL)	37 (26)	39 (30)	36 (26)	36 (24)	0.002
Apolipoprotein B (mg/dL)	104 (25)	103 (24)	103 (24)	107 (25)	<0.0001
HbA _{1c} (%)	6.3 (1.2)	6.3 (1.4)	6.3 (1.2)	6.3 (1.2)	0.203
HbA _{1c} (mmol/mol)	43 (13)	45 (15)	45 (13)	45 (13)	0.203
eGFR (mL/min/1.73 m ²) ‡	8.17 (20.1)	82.1 (20.7)	81.5 (20.1)	81.4 (19.6)	0.602

	All patients (n=3313)	Lp(a) tertile 1 10⁰-260 mg/dL (n=1146)	Lp(a) tertile 2 10¹-260 mg/dL (n=1065)	Lp(a) tertile 3 >260 mg/dL (n=1102)	p value*
hsCRP (mg/L)	3.4 (0.7-1.0)	3.6 (0-7.8)	3.4 (0-7.0)	3.2 (0-6.4)	0.037
Interleukin 6 (ng/L)	3.2 (1.0-5.4)	3.3 (0.9-5.7)	3.2 (1.1-5.3)	3.2 (1.1-5.3)	0.235
Fibrinogen (mg/dL)	377 (311-433)	370 (299-411)	380 (316-444)	381 (319-443)	0.619
Friesinger score	5.4 (3.9)	5.1 (3.9)	5.2 (4.0)	5.9 (3.8)	<0.0001
Coronary heart disease	2580 (78%)	867 (76%)	810 (76%)	903 (82%)	0.0004
Previous myocardial infarction	1365 (41%)	446 (39%)	448 (42%)	471 (43%)	0.144
Diabetes	1322 (40%)	467 (41%)	440 (41%)	415 (38%)	0.170
Taking lipid-lowering therapy	1607 (49%)	489 (43%)	529 (50%)	589 (53%)	<0.0001
Current or ex-smoker	2120 (64%)	741 (65%)	681 (64%)	698 (63%)	0.808
Hypertension	2409 (73%)	826 (72%)	762 (72%)	821 (75%)	0.255
Death from any cause	994 (30%)	361 (32%)	322 (30%)	311 (28%)	0.233
Cardiovascular deaths	621 (19%)	232 (20%)	186 (18%)	203 (19%)	0.129

Data are mean (SD) number (%), or median (IQR). Lp(a)=lipoprotein(a). SNP=single-nucleotide polymorphism. eGFR=estimated glomerular filtration rate. hsCRP=high sensitivity C-reactive protein.

* Comparison between tertiles of Lp(a).

[†]Ten participants carried minor alleles in *LPA* SNPs rs10455872 and rs3798220. Any *LPA* SNP minor allele information was available in 3287 participants. *LPA* SNP rs10455872 data were available in 3058 participants. *LPA* SNP rs3798220 data were available in 3286 participants. No information on *LPA* SNPs was available in 23 participants.

[‡]Calculated with the Chronic Kidney Disease Epidemiology Collaboration formula.